英国临床药学模式和方法课件_第1页
英国临床药学模式和方法课件_第2页
英国临床药学模式和方法课件_第3页
英国临床药学模式和方法课件_第4页
英国临床药学模式和方法课件_第5页
已阅读5页,还剩66页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、英国药学监护实践模式与方法 ( Pharmaceutical Care Practice in UK) 杨赴云 fyy0326sina 英国药学监护实践模式与方法 ( Pharmaceutic关于“Pharmaceutical Care” 的翻译“Pharmaceutical service” 药学服务 “Clinical Pharmacy ”临床药学 “Clinical Pharmacy service”临床药学服务 “Pharmaceutical care” 药学监护关于“Pharmaceutical Care” 的翻译“Care” 和 “Service”Care LONGMAN DICT

2、IONARY OF TEMPERARY ENGLISH Worry; anxiety; sorrow; grief; Charge; keeping; protection; responsibility;Serious attention;Carefulness in avoiding harm, damageService LONGMAN DICTIONARY OF TEMPERARY ENGLISH Work or duty done for someoneAn act or job done in favor of someone“Care” 和 “Service”Care LOCAR

3、E 大英汉词典烦恼,忧虑,操心注意,当心,小心,谨慎关切,关心,关怀,爱护看护,照管,照顾,管理,监护负责照管的事,负责,责任SERVICE 大英汉词典帮佣,业务,事务:尤指公共事务业务机构,行政部门劳役,服务性工作礼拜,宗教仪式CARE 大英汉词典ICU “Intensive Care Unit” “重症监护病房”CCU “Cardiac Care Unit” “心脏病监护病房” ICU “Intensive Care Unit” 药学服务Pharmaceutical Service范围广泛,所有与药学有关的服务。如,卫生行政药事管理部门,企业的制药技术服务,医院的药学服务等。医院药学部门所

4、提供的系统的服务,包括药品的配制和分发,提供与药物和疾病有关的信息,所有病人用药剂量的监测,审查医生处方并录入数据库等。(The Department of Pharmacy provides systems-based services including drug and disease state information, drug preparation and distribution, and dosage monitoring services for all patients. )药学服务Pharmaceutical Service范围广英国临床药学模式和方法课件英国临床药学模

5、式和方法课件英国临床药学模式和方法课件临床药学Clinical Pharmacy临床药学是由药学专业人员实施的,帮助临床最大效益的使用药物,并且将药物的毒性降到最小的学科。(Clinical pharmacy is a discipline concerned with the application of pharmaceutical expertise to help maximise drug efficacy and minimise drug toxicity in individual patients.)临床药学Clinical Pharmacy临床药学是由药学临床药学服务Cli

6、nical pharmacy service选择用药 药代动力学评价给药剂量和方法 对病人用药的咨询和教育 其他优化药物治疗的方法。 临床药学服务Clinical pharmacy servi药学监护Pharmaceutical care1990年Robert Cipolle,Linda Strand将药学监护定义为“以病人为中心的实践,实践者负责病人与用药有关的需求并为之负责” (Pharmaceutical care is a patient-centred practice in which the practitioner assumes responsibility for a pa

7、tients drug-related needs and is held accountable for this commitment.)药学监护Pharmaceutical care1990年R药学监护实践是一次实践针对一个病人。由三部分组成:评估病人的需求,制定监护计划,跟踪评价。 (It is built up one patient at a time.It has three components: assessment of the patients needs; development of a care plan; and follow up evaluation.)药学监

8、护实践是一次实践针对一个病人。由三部分组成:评估病人的Pharmaceutical servicesClinical pharmacy servicesPharmaceutical carePharmaceutical servicesPharmacA Typical Day of a Clinical Pharmacist in UK 英国临床药师的一天 A Typical Day of a Clinical Morning 8:30 12:00 (Coffee break 10:00 10:30)See the blackboard Those admission Those discha

9、rge Morning 8:30 12:00 For those who discharge today Prescribing their discharge drugsContact with their local pharmacistApproach to the patient For those who discharge todayFor those who were admittedMedical historyDrug historyThe knowledge of the patientPotential drug related problemsCare planFor

10、those who were admittedWard roundDoctors, nurse and pharmacistDiscussing about the drug related needs Ward roundReview the other patients who has potential problemsSigns and symptoms of the patientsLaboratory testsDocumented Afternoon 13:00 16:30Review the other patients who Ward meetingsNurse meeti

11、ngsPharmacists meetingsDispensingLibrary Ward meetingsFor the individual patient the Minnesota Model the British Model the Canadian Model the Australia ModelFor the individual patient The Minnesota ModelHolistic ApproachThe Minnesota ModelHolistic A药学监护计划(Pharmaceutical Care Plan)病人情况合并症疾病史及用药史协同治疗药

12、物曾有过的不良反应疾病及用药 病人条件 选择合适的药药学服务病人的旅程药学监护计划病人情况协同治疗药物 病人条件药学服务病人的旅 59岁女病人DA,因前胸剧烈疼痛,疼痛放射性的传播到左臂,急救中心到家中急救并送到SGH 医院急诊. 病人主诉: 胸部剧烈疼痛,呈放射性传到左 臂,恶心. 急救医生给diamorphin后 疼痛缓解.aspirin 300mgCase 59岁女病人DA,因前胸剧烈疼痛,疼痛放射性的传播到左臂入院检查: BP 137/81 mmHg pulse 62 bpm respiratory rates 16 temperature 36 SaO2 97% on air Her

13、 JVP, HS were normal her chest was clear.入院检查: 病史. Mrs DA 过去没有疾病记载 用药史 Mrs DA 住院前没有用过药物 ECG 显示 ST 段升高, 诊断 急性下壁心肌梗塞诊断病史. Mrs DA 过去没有疾病记载 用药史 M病人社会关系与丈夫一起住吸烟 每天25 支 喝酒 每周20 units. 病人社会关系与丈夫一起住Unit8g or 10 ml of pure alcoholHalf a pint of ordinary strength lager/beer/cider(3.5-4% A.B.V.) = 1 unitA 25ml

14、 pub measure of a spirit (40%A.B.V) =1 unitA small glass of wine(8-9%) =1 unit 1pint = 568ml 1unit=284ml beerUnitDay 1(09/01/04)streptokinase 1.5 mu iv 链激酶 metoclopramide 10mg iv 甲氧氯普胺 metoprolol 25mg 美托洛尔 Enoxaparin 40mg, 依诺肝素 aspirin 75mg, 阿司匹林 simvastatin 40mg 辛伐他丁 ramipril 2.5mg 雷米普利 Paracetamol

15、 1g 扑热息痛Day 1(09/01/04)稍后复查, ECG 显示病人恢复良好 ,病人生命体征很好BP 113/81 mmHgpulse 73bpm RR 17 稍后复查, ECG 显示病人恢复良好 ,病人生命体征很好Day 2(10/01/04)Mrs DA 今天没有胸痛心律为正常窦律感觉非常疲劳, 起床时头晕血压BP 73-97/34-69mmHg Metoprolol 25mg bd change to atenolol 25mg bd BP123/69mmHg Day 2(10/01/04) Day 4(12/01/04)无胸痛症状, 生命体征稳定活动良好,可以在病房内走动 停用e

16、noxaparin Day 4(12/01/04) Day 5(13/01/04) BP 83-113/47-65 Nicotine 帖剂 空腹血糖 10.7 mmol/l. 建议营养学家重新调整饮食 Ramipril 剂量由2.5mg增加到 5mg BD 今天可以出院 Day 5(13/0Date09/0110/0112/0113/01Na (135-145) mmol/l 138135140141K (3.5-5.0) mmol/l 4.24.04.1Urea (3.3-6.0) mmol/l 4.36.34.64.5Gluc (3.9-5.0) mmol/l 11.210.7Creat

17、(70-110) mol/l 56716258TnT (180mmHg), 感染性心内膜炎 yes 急性心梗溶栓治疗路径AMI 症状 ?请主治医生复查nStreptokinase 1.5MU 50ml 0.9% NaCl or 5% glucose over 1 hour Alteplase within 6-12 hours, 10mg iv, then 50mg intravenous infusion over 60 minutesSince the presence of antistreptokinase antibodies from day 5 to 12 months post

18、 administration may render further treatment during this time ineffective, it is important to document the patient had been given streptokinase and to issue the patient with a “streptokinase card” which includes the date of administration. Streptokinase 1.5MU 50ml 0.9%英国临床药学模式和方法课件LifestyleImproving

19、 diet Advise patients not to take supplements containing beta-carotene.Do not advise patients to take antioxidant supplements (vitamin E and/or C) or folic acid to reduce cardiovascular risk.Advise patients to consume at least 7 g of omega 3 fatty acids per week from two to four portions of oily fis

20、h.Consider providing at least 1 g daily of omega-3-acid ethyl esters treatment licensed for secondary prevention post MI for up to 4 years for patients who have had an MI within 3 months and are not achieving 7 g of omega 3 fatty acids per week.Do not routinely initiate omega-3-acid ethyl esters sup

21、plements for patients who have had an MI more than 3 months earlier.Encourage patients to eat a Mediterranean-style diet.LifestyleImproving diet Delivering dietary Give consistent healthy eating advice that is tailored to the patients needs and that can be extended advice to the whole family.Offer p

22、atients an individual consultation to discuss diet, including their current eating habits, and advice on improving their diet.Delivering dietary Controlling alcohol Advise patients to keep weekly alcohol consumption within safe limits (no more than 21 units of consumption alcohol per week for men or

23、 14 units per week for women) and to avoid binge drinking.Smoking cessation Advise smokers to quit and offer assistance from a smoking cessation service.Offer smokers who have expressed a desire to quit support, advice and referral to an intensive support service.If a patient is unable or unwilling

24、to accept a referral, offer pharmacotherapy.Controlling weight Offer overweight and obese patients advice and support to achieve and maintain a healthy weight.Controlling alcohol Improving physical activity levels Encourage patients to undertake sufficient regular physical activity to increase exerc

25、ise capacity.They should aim to be physically active for 2030 minutes a day to the point of slight breathlessness. For patients not achieving this, advise them to increase their activity in a step-by-step way, aiming to increase their exercise capacity. They should start at a level that is comfortab

26、le, and increase the duration and intensity of activity as they gain fitness.Discuss current and past activity levels and preferences with patients.The benefit of exercise may be enhanced by tailored advice from a suitably qualified professional.Improving physical activity leCardiac rehabilitation a

27、fter an acute MICardiac rehabilitation programmes have been consistently shown to reduce mortality rates in CHD patients. Cardiac rehabilitation is the coordinated sum of interventions required to ensure the best possible physical, psychological and social conditions to enable the CHD patient to pre

28、serve or resume optimal functioning in society. It also aims to slow or reverse progression of the disease. Cardiac rehabilitation cannot be regarded as an isolated form or stage of therapy, but must be integrated within secondary prevention services, of which it forms only one facet (WHO definition

29、, 1993).Cardiac rehabilitation in patients after MI reduces all-cause and cardiovascular mortality rates provided it includes an exercise component Cardiac rehabilitation after aOffer all patients who have had an acute MI treatment with a combination of the following drugs: ACE inhibitor aspirin bet

30、a-blocker statin.Drug therapy Offer all patients who have haACE inhibitors Offer ACE inhibitors early after presentation and titrate upwards to the maximum tolerated or target dose.Do not routinely prescribe ARBs unless the patient is intolerant or allergic to an ACE inhibitor.Continue ACE inhibitor

31、s indefinitely in patients with preserved LV function or LVSD, whether or not they have heart failure symptoms.Early after an acute MI, do not routinely use the combination of ACE inhibitor/ARB for patients with heart failure and/or LVSD.ACE inhibitors Assessment/monitoringAssess LV function in all

32、patients who have had an MI.Measure renal function, serum electrolytes and BP before starting an ACE inhibitor or ARB and again within 1 or 2 weeks.Monitor patients as the dose is titrated and more frequently for patients at increased risk of deterioration in renal function.Monitor patients with chr

33、onic heart failure Assessment/monitoringAntiplatelet therapyOffer aspirin and continue indefinitely.Do not offer clopidogrel alone as first-line therapy but consider it for patients with aspirin hypersensitivity. If the patient has not been treated with a combination of aspirin and clopidogrel durin

34、g the acute phase of an MI, do not routinely initiate this combination.- Clopidogrel in combination with low-dose aspirin is recommended in the management of non-ST-segment-elevation acute coronary syndrome in people who are at moderate to high risk of MI or death. It is recommended that this combin

35、ation is continued for 12 months after the most recent acute episode. Thereafter standard care, including low-dose aspirin alone, is recommended.Antiplatelet therapyFor patients after a STEMI treated with the combination of aspirin and clopidogrel during the first 24 hours, this combination should b

36、e continued for at least 4 weeks. Thereafter standard treatment including low-dose aspirin should be given unless there are other indications to continue dual antiplatelet therapy.For patients with a history of dyspepsia, consider a PPI and low-dose aspirin. For patients with a history of aspirin-in

37、duced ulcer bleeding whose ulcers have healed and who are H. pylori negative,consider a full-dose PPI and low-dose aspirin. 英国临床药学模式和方法课件Beta-blockersOffer a beta-blocker as soon as the patient is clinically stable and titrate upwards to the maximum tolerated dose.Continue treatment indefinitely.For

38、 patients with LVSD being offered treatment, a beta-blocker licensed for use in heart failure may be preferred. Carvedilol bisoprololBeta-blockersPotassium channel activatorsNicorandil is not recommended to reduce cardiovascular risk.Potassium channel activatorsVitamin K antagonistsHigh-intensity wa

39、rfarin (INR 3) should not be considered as an alternative to aspirin in first-line treatment.For patients unable to take aspirin or clopidogrel, consider moderate-intensity warfarin (INR 23) for up to 4 years and possibly longer.The combination of warfarin and clopidogrel is not routinely recommende

40、d.Vitamin K antagonistsCalcium channel blockersDo not routinely use calcium channel blockers for secondary prevention. If beta-blockers are contraindicated or need to be discontinued, consider diltiazem or verapamil for secondary prevention in patients without pulmonary congestion or LVSD.For patien

41、ts who are stable, calcium channel blockers may be used to treat hypertension and/or angina. For patients with heart failure, use amlodipine and avoid verapamil, diltiazem and short-acting dihydropyridine agents in line with NICE clinical guidelineCalcium channel blockersAldosterone antagonistsFor p

42、atients with symptoms and/or signs of heart failure and LVSD, initiate treatment with an aldosterone antagonist licensed for post-MI treatment within 314 days of the MI, preferably after ACE inhibitor therapy. For patients with clinical heart failure and LVSD already being treated with an aldosteron

43、e antagonist for a concomitant condition, continue with the aldosterone antagonist or an alternative, licensed for early post-MI treatment.Aldosterone antagonistsAssessment/monitoringMonitor renal function and serum potassium before and during treatment. If hyperkalaemia is a problem, halve the dose

44、 or stop the treatment.Assessment/monitoringStatins and other lipid lowering agentsStatin treatment is recommended for adults with clinical evidence of CVD and should be offered as soon as possible.Discuss the risks and benefits of treatment with the patient, taking into account comorbidities and li

45、fe expectancy.Start therapy with a drug with a low acquisition cost (taking into account required daily dose and product price per dose).Statins and other lipid loweriFor patients intolerant of statins, other lipid lowering agents should be considered.Reduce or stop the dose of statins if there are

46、issues surrounding the metabolic pathway, food and/or drug interactions and/or concomitant illness.Discontinue the statin and seek specialist advice if patients develop peripheral neuropathy that may be attributable to the statin treatment.For patients intolerant of staAssessment/monitoringMeasure b

47、aseline liver enzymes before initiation.Do not routinely exclude patients who have raised liver enzymes from treatment.Routine monitoring of creatine kinase in asymptomatic patients is not recommended, but should be measured in patients who develop muscle symptoms.Assessment/monitoringPatient Educat

48、ion Education and stress management programmes reduce cardiac mortality and MI recurrence in post MI patients Questions you might like to ask about medicinesHow long will I have to take the medicines for?What is the best time of day to take the medicines?Are there any serious side effects associated

49、 with the medicines?What should I do if I get any side effects?Are there any foods or drinks that I should avoid?What sort of improvements might I expect to notice?How long will it take to notice any effect?Patient Education Educatio药学监护计划(PHARMACEUTICAL CARE PLAN) 日期Date监护点/期望结果Care Issues /Desired

50、 output 措施 Action 结果OutputDay1 (09/01) Drug history -ensure the drug history accurately and correctly Check DH-discuss with patient -medical notes-GP/community pharmacistPatient didnt take any drugs on admission Acute treatment on acute myocardial infarction-ensure appropriate acute treatment Check to ensure-aspirin -streptokinase-metoclopramide-b blockerNo contraindication, all drug prescribed and given appropriately 药学监护计划(PHARMACEUTICAL CARE PLADateCare Issues /Desired output Action OutputSecondary prevention

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论